RT Journal Article
SR Electronic
T1 Heightened resistance to type 1 interferons characterizes HIV-1 at transmission and following analytical treatment interruption
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.24.20181149
DO 10.1101/2020.08.24.20181149
A1 Gondim, Marcos V. P.
A1 Sherrill-Mix, Scott
A1 Bibollet-Ruche, Frederic
A1 Russell, Ronnie M.
A1 Trimboli, Stephanie
A1 Smith, Andrew G.
A1 Li, Yingying
A1 Liu, Weimin
A1 Avitto, Alexa N.
A1 DeVoto, Julia
A1 Connell, Jesse
A1 Fenton-May, Angharad E.
A1 Pellegrino, Pierre
A1 Williams, Ian
A1 Papasavvas, Emmanouil
A1 Lorenzi, Julio C. C.
A1 Salantes, D. Brenda
A1 Mampe, Felicity
A1 Monroy, M. Alexandra
A1 Cohen, Yehuda Z.
A1 Heath, Sonya
A1 Saag, Michael S.
A1 Montaner, Luis J.
A1 Collman, Ronald G.
A1 Siliciano, Janet M.
A1 Siliciano, Robert F.
A1 Plenderleith, Lindsey
A1 Sharp, Paul M.
A1 Caskey, Marina
A1 Nussenzweig, Michel C.
A1 Shaw, George M.
A1 Borrow, Persephone
A1 Bar, Katharine J.
A1 Hahn, Beatrice H.
YR 2020
UL http://medrxiv.org/content/early/2020/08/28/2020.08.24.20181149.abstract
AB Type 1 interferons (IFN-I) are potent innate antiviral effectors that constrain HIV-1 transmission. However, harnessing these cytokines for HIV-1 cure strategies has been hampered by an incomplete understanding of their anti-viral activities at later stages of infection. Here, we characterized the IFN-I sensitivity of 500 clonally-derived HIV-1 isolates from plasma and CD4+ T cells of 26 individuals sampled longitudinally following transmission and/or after antiretroviral therapy (ART) and analytical treatment interruption (ATI). Determining the concentration of IFNα2 and IFNβ that reduced HIV-1 replication by 50% (IC50), we found remarkably consistent changes in the sensitivity of viruses to IFN-I inhibition, both across individuals and over time. IFN-I resistance was uniformly high during acute infection, decreased in all subjects in the first year post-infection, was reacquired concomitant with CD4+ T cell loss, and remained elevated in subjects with accelerated disease. Isolates obtained by viral outgrowth during suppressive ART were relatively IFN-I sensitive, resembling viruses circulating just prior to ART initiation. However, viruses that rebounded following treatment interruption displayed the highest levels of IFNα2 and IFNβ resistance observed at any time during the infection course. These findings indicate a dynamic interplay between host innate immune responses and the evolving HIV-1 quasispecies, with the relative contribution of IFN-I to HIV-1 control impacted by both ART and ATI. Although elevated at transmission, IFN-mediated pressures are the highest during viral rebound, limiting the viruses that successfully reactivate from latency.One Sentence Summary HIV-1 resistance to IFN-I is highest during acute infection and following analytic treatment interruption, indicating a dynamic interplay between host innate immunity and virus biology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by grants from the National Institutes of Health (U01 AI 129825 to M.C., U01 AI 065279 to L.J.M., UM1 Al 126620 to L.J.M., K.J.B., and B.H.H., P30 AI 045008 to R.G.C, L.J.M., K.J.B., and B.H.H., UM1 AI 126619 to P.B., UM1 AI100663 to M.C.N., R01 AI 111789 to B.H.H., R01 AI 114266 to B.H.H.), the Medical Research Council (MR/K012037 to P.B.) and the Bill and Melinda Gates Foundation (Collaboration for AIDS Vaccine Discovery grant OPP1092074 to M.C. N.). S.S.-M. and R.M.R. were supported by a training grant (T32 AI 007632). P.B. is a Jenner Institute Investigator.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the London cohort study was provided by the National Health Service Camden/Islington Community Local Research Ethics Committee. The use of stored (de-identified) samples from participant WEAU was approved by the University of Alabama at Birmingham Institutional Review Board. Plasma and viably frozen PBMC samples were also obtained from 16 individuals who participated in six different treatment interruption and latency trials (MNU-0628, NCT02825797, NCT0246322, NCT00051818, NCT02227277, NCT02588586). These materials were obtained from existing repositories and their use was approved by the respective Institutional Review Boards as previously described.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesHIV-1 sequences have been deposited in GenBank as listed in table S5. Analysis code is available at https://github.com/sherrillmix/ifnDynamicsModels and will be archived on Zenodo prior to publication.